Table 2.
Results from the Vertigo Integrated Therapy in patients with Ménière's disease.
| VIT Group | Asymptomatic | Improved | No change | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 days | 120 days | 60 days | 120 days | 60 days | 120 days | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |
| Betahistine | 6 | 9.7 | 31 | 50.0 | 45 | 72.6 | 24 | 38.7 | 11 | 17.7 | 7 | 11.3 |
| Cinnarizine | 4 | 6.7 | 17 | 28.3 | 36 | 60.0 | 28 | 46.7 | 20 | 33.3 | 15 | 25.0 |
| Clonazepam | 3 | 6.8 | 11 | 25.0 | 24 | 54.5 | 20 | 45.5 | 17 | 38.6 | 13 | 29.5 |
| Flunarizine | 2 | 4.9 | 8 | 19.5 | 18 | 43.9 | 19 | 46.3 | 21 | 51.2 | 14 | 34.1 |
| EGb 761 | 2 | 4.9 | 8 | 19.5 | 17 | 41.5 | 18 | 43.9 | 22 | 53.7 | 15 | 36.6 |
| No medication | 0 | 0.0 | 5 | 14.3 | 5 | 14.3 | 14 | 14.0 | 30 | 85.7 | 16 | 45.7 |